Aubagio FDA OK in hand, but can Sanofi/Genzyme MS drug compete?
This article was originally published in Scrip
Executive Summary
With the US FDA's approval late on 12 September of Genzyme's Aubagio (teriflunomide), US patients with relapsing forms of multiple sclerosis now have another oral option to treat the chronic, inflammatory, autoimmune central nervous system disease.